Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Unlabelled: Pathologic signaling via the receptor for advanced glycation end products (RAGE) is critical to diabetic kidney disease (DKD) development, whereas RAGE deletion is renoprotective. Noncoding RNAs (ncRNAs), including miRNAs, also play key roles in DKD, including in renal fibrosis. However, the involvement of ncRNAs in RAGE signaling remains unclear. This study investigated the regulation of ncRNAs by RAGE and assessed renal expression of ncRNAs, miRNAs, and fibrotic/inflammatory markers in diabetic RAGE-knockout and wild-type (WT) mice as well as in mesangial cells (MCs) obtained from these mice. Diabetes induction in both RAGE-/- and WT mice was associated with elevated renal expression of miR-214 and its host ncRNA, Dnm3os. miR-214 and Dnm3os levels were remarkably higher in RAGE-/- MCs compared with WT MCs. Overexpression of miR-214 in WT MCs reduced fibrotic/inflammatory gene expression, whereas its inhibition increased these markers. Human DKD tissue demonstrated higher DNM3os expression compared with controls. Notably, miR-214 targeted the RAGE signaling mediator protein diaphanous homolog 1 (DIAPH1), whereas Dnm3os had an opposite effect, enhancing fibrosis and inflammation. miR-214 administration in a DKD mouse model significantly reduced renal fibrosis. These findings suggest a novel mechanism by which miR-214 and Dnm3os act as negative and positive regulators of fibrosis via the RAGE-DIAPH1 axis.

Article Highlights: The mechanism of renoprotection as a result of receptor for advanced glycation end products (RAGE) deletion is unclear but seems to involve noncoding (ncRNAs). We investigated the regulation of ncRNAs by RAGE in the context of diabetic kidney disease (DKD), exploring the renal expression of ncRNAs, microRNAs, and fibrotic and inflammatory markers in diabetic RAGE-knockout (KO) and wild-type mice, as well as in mesangial cells (MCs) obtained ex vivo from these mice. Elevated miR-214 levels in diabetic RAGE-KO mice had antifibrotic effects by targeting protein diaphanous homolog 1 (DIAPH1). In contrast, the coexpressed host ncRNA, Dnm3os, had an opposite effect, enhancing fibrosis and inflammation in MCs. We propose a novel regulatory mechanism in DKD involving miR-214 and Dnm3os as negative and positive regulators of fibrosis, respectively, through the RAGE-DIAPH1 axis. Targeting DIAPH1 through miR-214 may represent a novel therapeutic strategy for DKD.

Download full-text PDF

Source
http://dx.doi.org/10.2337/db24-0121DOI Listing

Publication Analysis

Top Keywords

fibrosis inflammation
12
rage signaling
12
diabetic kidney
12
kidney disease
12
ncrnas rage
12
renal expression
12
mir-214 dnm3os
12
mir-214
10
dnm3os
8
rage
8

Similar Publications

Chronic diarrhea is a frequent gastrointestinal complication in both type 1 (T1D) and type 2 diabetes (T2D), although the underlying mechanisms differ: T1D is linked to autonomic neuropathy and disrupted transporter regulation, while T2D is often linked to medications and intestinal inflammation. Using streptozotocin-induced mouse models of T1D and T2D, we observed increased luminal fluid in the small intestine of both. Given the role of Na⁺/H⁺ exchanger 3 (NHE3) in fluid absorption and its loss in most diarrheal diseases, we examined NHE3 expression across intestinal segments.

View Article and Find Full Text PDF

Cardiovascular-Kidney-Metabolic (CKM) syndrome, a newly defined systemic disorder, is characterized by the pathological interplay among diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). Recent studies have identified chronic inflammation not only as a central mediator in the pathological progression of CKM syndrome but also as a pivotal molecular hub that drives coordinated damage across multiple organ systems. Mechanistic investigations have revealed that aberrant activation of signaling pathways such as NF-κB, Wnt, PI3K-AKT, JAK-STAT, and PPAR constitutes a complex inflammatory regulatory network.

View Article and Find Full Text PDF

 Keloid scarring and Metabolic Syndrome (MS) are distinct conditions marked by chronic inflammation and tissue dysregulation, suggesting shared pathogenic mechanisms. Identifying common regulatory genes could unveil novel therapeutic targets. Methods.

View Article and Find Full Text PDF

The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).

View Article and Find Full Text PDF

Myopathology and Immune Profile of Granulomatous Myositis in Sarcoid Myopathy.

Neuropathol Appl Neurobiol

October 2025

Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Aims: Sarcoid myopathy (SaM) is characterised by granulomatous myositis (GM) and can overlap with inclusion body myositis (IBM), a late-onset chronic idiopathic inflammatory myopathy with a still enigmatic pathogenesis. As GM can occur in different clinical contexts, we aimed to examine the histomorphologic features and gene expression profiles in cases of definite SaM that may inform diagnostic and therapeutic considerations.

Methods: We performed a multidimensional characterisation of muscle biopsy specimens from patients with 'pure SaM' (n=17), SaM with concomitant IBM (SaM-IBM) (n=2), including histopathologic and ultrastructural analysis in addition to quantitative real-time polymerase chain reaction.

View Article and Find Full Text PDF